` RNTX (Aileron Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

A
RNTX
vs
S&P 500

Over the past 12 months, RNTX has underperformed S&P 500, delivering a return of -49% compared to the S&P 500's +13% growth.

Stocks Performance
RNTX vs S&P 500

Loading
RNTX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RNTX vs S&P 500

Loading
RNTX
S&P 500
Difference
www.alphaspread.com

Performance By Year
RNTX vs S&P 500

Loading
RNTX
S&P 500
Add Stock

Competitors Performance
Aileron Therapeutics Inc vs Peers

S&P 500
RNTX
ABBV
AMGN
GILD
VRTX
Add Stock

Aileron Therapeutics Inc
Glance View

Market Cap
30.8m USD
Industry
Biotechnology

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2017-06-29. The firm is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

RNTX Intrinsic Value
0.55 USD
Overvaluation 61%
Intrinsic Value
Price
A
Back to Top